Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Enterprise Value (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Enterprise Value data on record, last reported at -$30.1 million in Q4 2025.

  • For Q4 2025, Enterprise Value rose 34.93% year-over-year to -$30.1 million; the TTM value through Dec 2025 reached -$30.1 million, up 34.93%, while the annual FY2025 figure was -$30.1 million, 34.93% up from the prior year.
  • Enterprise Value reached -$30.1 million in Q4 2025 per VRCA's latest filing, down from -$21.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$15.4 million in Q2 2025 and bottomed at -$84.3 million in Q3 2023.
  • Average Enterprise Value over 5 years is -$39.1 million, with a median of -$33.4 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: plummeted 159.6% in 2023, then soared 72.72% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$15.8 million in 2021, then plummeted by 117.58% to -$34.3 million in 2022, then crashed by 102.92% to -$69.5 million in 2023, then soared by 33.38% to -$46.3 million in 2024, then soared by 34.93% to -$30.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$30.1 million in Q4 2025, -$21.1 million in Q3 2025, and -$15.4 million in Q2 2025.